Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
更正:PARP抑制剂尼拉帕尼治疗BAP1和其他DNA损伤反应通路缺陷型肿瘤的II期试验
期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-25-00369
George, Thomas J; Lee, Ji-Hyun; DeRemer, David L; Hosein, Peter J; Staal, Steven; Markham, Merry Jennifer; Jones, Dennie; Daily, Karen C; Chatzkel, Jonathan A; Ramnaraign, Brian H; Close, Julia L; Ezenwajiaku, Nkiruka; Murphy, Martina C; Allegra, Carmen J; Rogers, Sherise; Zhang, Zhongyue; Li, Derek; Srinivasan, Gayathri; Shaheen, Montaser; Hromas, Robert